美国领先仿生有限公司（Advanced Bionics） www.bionicear.com.cn www.bionicear.com.cn  www.sonova.com
2009年11月9日美国唯一生产人工耳蜗的专业公司美国领先仿生有限公司（Advanced Bionics）宣布和瑞士Sonova集团达成并购协议。
美国领先仿生有限公司（Advanced Bionics）是全球领先的从事人工耳蜗的研发生产和技术创新的专业公司，公司的总部位于美国加州洛杉矶生物科学园。 　　
　　上个世纪80年代，加利福尼亚大学的旧金山分校的科学家独立开发出了新型号的多通道人工耳蜗，Alfred E.Mann先生和该校洽谈后获得该技术，于1993年出资创建了美国领先仿生公司。

　　作为人工耳蜗领域的创新者，秉持“病人至上、品质第一”的服务宗旨，依托美国领先的电子技术和全球范围内的研究中心，美国领先仿生有限公司拥有的最多的人工耳蜗注册专利技术，我们以其强大的技术实力和锐意创新能力，成为该领域无可争议的领导者。

我们的领先历史： 我们的使命：

第一个提供设计多个程序存储空间的声音处理器。
第一个提供音量和灵敏度控制。
第一个提供环抱耳蜗轴的电极阵列。
第一个提供可充电电池技术。
第一个提供不同声音处理策略的选择能力。
第一个提供自然的麦克风位置。
第一个，并且是唯一的提供多个电极同时刺激。
第一个，并且是唯一的提供高分辨率声音策略。
第一个能够引发神经随机响应的正常听觉反应方式。
第一个提供通道定向技术。
第一个提供120个通道。
第一个同Phonak SmartLink蓝牙系统兼容
......
　　创新和研发可植入的仿生技术使得患神经疾病的人们能克服自身的障碍，改善他们的生活，使聋者复聪、盲者复明、跛者复行！


执行总裁Jeff Grainer这样描述公司：
　　“我们正在努力建立这样一个公司，在这里，产品可靠性是最永远放在第一位的，创新开发和进入市场的时间是我们成功的关键，任何想象丰富的念头都受到鼓励，纪律和团队工作是我们的组织成分，我们的员工懂得一起投身于一项有意义的事业，他们工作的使命就是：改善他人的生活！” 
        
Advanced Bionics® Corporation is a global leader in developing the most reliable, best performing cochlear implant devices in the world. Founded in 1993, AB is the only American company developing cutting-edge cochlear implant technology that restores hearing to the deaf and allows our recipients to hear their best today, tomorrow, and always. We support patients, clinicians, and physicians through the latest scientific research, technology development, educational resources, attentive customer service, community involvement, and more.

AB evolved from two highly successful companies that developed and marketed innovative medical devices; one created new generation pacemakers, and the other developed microinfusion systems (miniature drug delivery pumps used in the treatment of diabetes). Our talented group of technologists and professionals from all over the world are driven to succeed, work with integrity, and stay firmly committed to quality.

Today, AB remains dedicated to improving lives by developing, manufacturing, and distributing the world’s most reliable, best performing cochlear implant system.

Our Mission
At AB, our mission is to improve lives by developing, manufacturing, marketing, and supporting high-quality, state-of-the-art hearing technology for those with severe to profound hearing loss.

Our commitment to providing the best possible hearing experience for our recipients by putting patients first remains at the forefront of all that we do. The trust our recipients place in us is the highest honor and inspires us to strive for excellence each and every day.

Our Culture
Our culture is best described by our people: highly intelligent, spirited, ambitious, and dedicated. We attract innovative technologists and distinguished professionals from all over the world who are committed to improving the lives of those with severe to profound hearing loss.

The culture of AB is shaped daily by our unique mission, the leaders who successfully drive the business, and the staff members from all across the globe who help our recipients hear their best.

"We are building a company with a culture where reliability matters most, where innovation and time to market are the keys to our financial success, where crazy ideas are encouraged, where discipline and teamwork are part of our fabric, and where our employees understand the privilege of being engaged together in a business whose mission is to improve the lives of others."

—Jeff Greiner, President and Co-Chief Executive Officer

Our Focus
At AB, we focus on putting patients first in everything that we do. As part of our firm commitment to patients, we’ve enacted eight core initiatives, each designed to improve the lives of our recipients on their journey to hearing with AB.

Reliability: Deliver reliable cochlear implant systems.
Improvements: Make improvements on ease of use and aesthetics of our cochlear implant systems.
Communicate Differences: Communicate the performance differences between devices.
Make It Easy: Make it easy for patients and clinicians to get what they need.
Reimbursement: Help patients and clinicians access appropriate insurance reimbursement.
Legacy Patients: Support legacy patients throughout their journey to hearing.
Global Company: Address the needs of our patients across the world.
Lifelong Partner: Remain reasonably profitable in order to be a lifelong partner to our recipients.
Leadership
Jeff Greiner
President and Chief Executive Officer
A lawyer by training and an Air Force Academy graduate, Jeff Greiner has been the operational leader of Advanced Bionics® from its beginning.

He served a commitment to the Air Force as part of the Judge Advocate General’s Department. He left the Air Force in 1986 and became the Associate General Counsel for Siemens-Pacesetter and the Acting General Counsel for MiniMed Technologies, Limited, the predecessor entity which produced both MiniMed, Inc. and Advanced Bionics Corporation.

In 1992, Mr. Greiner left Siemens-Pacesetter to lead and build AB into a leading neurological device company. He has grown the company from seven employees in 1992 to over 600 employees in 2009 with an emphasis on leadership and the creation of an innovative and spirited culture, where creativity and discipline are the keys to producing exceptional technology that improves lives.

He holds a B.S. degree in Economics with highest honors from the United States Air Force Academy (1974), a JD degree from UCLA (1977), and an LLM with highest honors from George Washington University (1985).

Al Mann
Chairman and Founder
Alfred E. Mann serves as Chairman of the Board and CEO of MannKind Corporation, a diversified biopharmaceutical company focused on the development of novel therapeutics and drug-delivery technologies for the treatment of diabetes, cancer, autoimmune, and inflammatory diseases. MannKind’s lead product mimics the insulin kinetics of a normal pancreas, creating a new therapy paradigm for diabetes. In 1993, Mr. Mann also founded and began serving as Chairman and co-CEO of Advanced Bionics Corporation (“"Bionics”).

Additionally, Mr. Mann founded and served as the Chairman of the Board and Chief Executive Officer of MiniMed, Inc. from its founding in 1993 until August 2001 when it was